2.Éû¿ÕÇò¼Á¥¸¥¹¥È¥í¥Õ¥£¡¼¤Î¸¦µæ¤Î¸½¾õ¤È¸¦µæÈɤμèÁÈ

A¡¥ALD¤Î±Ö³Ø

ALDÁ´ÂΤÎȯ¾ÉÉÑÅÙ

Êó¹ð¤Ë¤è¤Ã¤ÆÃË»Ò2Ëü¿Í¡Á20Ëü¿Í¤Ë£±Ì¾¤ÈÂ礭¤ÊÉý¤¬¤¢¤ê¤Þ¤¹¤¬¡¢ Moser¤é¤ÏÊƹñ¤Ë¤ª¤±¤ëÃËÀ­´µ¼Ô¤È½÷À­ÊÝ°ø¼Ô¤ò¹ç¤ï¤»¤¿ÉÑÅÙ¤Ï1/18,000¿Í¤È»î»»¤·¤Æ¤¤¤Þ¤¹¡£ ¤³¤ì¤ÏñÆȤÎÀèÅ·Âå¼Õ°Û¾ï¾É¤È¤·¤Æ¤Ï¤«¤Ê¤ê¹â¤¤ÉÑÅ٤Ǥ¢¤ë¤³¤È¤Ë¤Ê¤ê¤Þ¤¹¡£ Êƹñ¤Ë¤ªs¤±¤ë¥Õ¥§¥Ë¥ë¥±¥È¥óÇ¢¾É¤ÎÉÑÅÙ¤Ï1/12,000¿Í¤Ç¤¹¤«¤é¡¢ ¤½¤ì¤Ë¶á¤¤ÉÑÅ٤Ȥʤê¤Þ¤¹¡£¤Þ¤¿¥Õ¥é¥ó¥¹¤Î´µ¼ÔÉÑÅÙ¤Ï1/22,500¿Í¤ÈÊó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£

ÆüËܤˤª¤±¤ëÉÑÅ٤ˤĤ¤¤Æ¤ÏËܸ¦µæÈɤ¬1990ǯ¡Á1999ǯ¤Î10ǯ´Ö¤Ë¤Ä¤¤¤ÆÁ´¹ñÄ´ºº¤ò¹Ô¤¤¡¢ 1/30,000¡Á50,000¿Í¤Ç¤¢¤í¤¦¤È¿ä·×¤ò½Ð¤·¤Þ¤·¤¿¡£¤³¤ì¤Ï¸åÊý»ëŪ¤Ê¥¢¥ó¥±¡¼¥ÈÄ´ºº¤Ç¤¹¤Î¤Ç¡¢ ¤Þ¤Àϳ¤ì¤¬¤¢¤ë¤È¹Í¤¨¤é¤ì¡¢¤ª¤½¤é¤¯²¤ÊƤÈÂ纹¤Ê¤¤È¯¾ÉÉÑÅ٤Ǥ¢¤í¤¦¤È¿ä¬¤µ¤ì¤Þ¤¹¡£

É·¿Ê̤Îȯ¾ÉÉÑÅÙ

²¤ÊƤΥǡ¼¥¿¤Ç¤Ï¾®»ù·¿31¡Á40¡ó¡¢»×½Õ´ü·¿5¡óÁ°¸å¡¢ AMN 25¡Á46¡ó¡¢À®¿ÍÂçǾ·¿2¡Á16¡ó¡¢AddisonɤΤß6¡Á14¡ó¡¢ ̵¾É¾õ¡Êȯ¾ÉÁ°¡Ë4¡Á10¡ó¤ÈÊó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£ ¹ñ¤Ë¤è¤Ã¤Æº¹¤¬¸«¤é¤ì¡¢¥Õ¥é¥ó¥¹¡¦¥ª¥é¥ó¥À¤Ç¤ÏAMN¤¬Â¿¤¯¡¢¥¹¥Ú¥¤¥ó¤Ç¤ÏÀ®¿ÍÂçǾ·¿¤¬16%¤È¿¤¯Ç§¤á¤é¤ì¤Þ¤¹¡£

ÆüËܤˤª¤±¤ëÄ´ºº¤Ç¤Ï¾®»ù·¿29.9¡ó¡¢»×½Õ´ü·¿9.1¡ó¡¢ AMN25.3¡ó¡¢À®¿ÍÂçǾ·¿21.4¡ó¡¢¾®Ç¾¡¦Ç¾´´·¿8.4¡ó¡¢È¯¾ÉÁ°4.5¡ó¤È¤¤¤¦·ë²Ì¤Ç¤·¤¿¡£ ²¤ÊƤËÈæ¤ÙÀ®¿ÍÂçǾ·¿¤¬Â¿¤¯¡¢¾®Ç¾Ç¾´´·¿¤âÆüËܤÎÆÃħ¤È¸À¤¨¤Þ¤¹¡£ ¤Þ¤¿ËÜË®¤Ë¤ª¤±¤ë²áµî¤Î¥Ç¡¼¥¿¤Ç¤Ï¾®»ù´µ¼Ô¤¬Ìó2/3¤òÀê¤á¤Æ¤¤¤Þ¤·¤¿¤¬¡¢ º£²ó¤ÎÄ´ºº¤Ç¤Ï¾®»ù´µ¼Ô¤ÈÀ®¿Í´µ¼Ô¤ÎÈæΨ¤Ï¤Û¤Ü²¤ÊƤȶá»÷¤·¤Æ¤¤¤Þ¤¹¡£

ALD¸¦µæÈɤˤè¤ëÁ´¹ñ±Ö³ØÄ´ºº·ë²Ì¤Ë¤Ä¤¤¤Æ

ȯ¾ÉǯÎ𡧾®»ù·¿¤ÎÊ¿¶Ñ¤ÏÌ󣷺Фǡ¢¾®³Ø¹»Äã³Øǯ¤ËȯÉÂ¥Ô¡¼¥¯¤¬¤¢¤ê¤Þ¤¹¡£ºÇ¤âÁᤤȯ¾É¤Ï£²ºÐ¤Ç¤·¤¿¡£AMN 30.2ºÐ¡¢À®¿ÍÂçǾ·¿36.8ºÐ¡¢¾®Ç¾¡¦Ç¾´´·¿38.0ºÐ¤Ç¤·¤¿¡£À®¿Í¤ÎȯÉÂ¥Ô¡¼¥¯¤Ï20Âå¸åȾ¤«¤é30ÂåÁ°È¾¤Ç¤¹¡£

ȯɤ«¤é¿ÇÃǤޤǤδü´Ö¡§¾®»ù·¿¤ÏȯɸåÊ¿¶Ñ0.9ǯ¤Ç¿ÇÃǤµ¤ì¤Æ¤¤¤Þ¤¹¤¬¡¢¹ü¿ñ°Ü¿¢¤ò¼õ¤±¤ë¤Ë¤Ï¤¹¤Ç¤ËÃÙ¤¤¤È¹Í¤¨¤é¤ì¤Þ¤¹¡£À®¿ÍÎã¤Ç¤Ï¿ÇÃǤޤǤ˿ôǯ¤òÍפ¹¤ëÎã¤â¿¤¯¤ß¤é¤ì¤Þ¤¹¡£

½éȯ¾É¾õ¡§¾®»ù·¿¤Ç¤ÏÃÎŪÂà¹Ô¡¦»ëÎϾ㳲¤¬ºÇ¤â¿¤¯¡¢¼¡¤¤¤ÇÀº¿À¾É¾õ¡¦Êâ¹Ô¾ã³²¡¦Ä°ÎϾ㳲¤È¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£»×½Õ´ü¤Ç¤Ï»ëÎÏ¡¦Êâ¹Ô¾ã³²¤¬Â¿¤¯Ç§¤á¤é¤ì¤Þ¤¹¡£AMN¤È¾®Ç¾¡¦Ç¾´´·¿¤Ç¤Ï¡¢ÅöÁ³¤Î¤³¤È¤Ç¤¹¤¬¡¢Êâ¹Ô¾ã³²¤¬°µÅÝŪ¤Ë¿¤¯Ç§¤á¤é¤ì¤Þ¤·¤¿¡£À®¿ÍÂçǾ·¿¤Ç¤ÏÀº¿À¾É¾õ¤¬ºÇ¤â¿¤¤½éȯ¾É¾õ¤Ç¤¹¡£

·Ð²á¡§¾®»ù·¿¤Ï£²Ç¯°ÊÆâ¤ËÓë²¼¾ã³²¡¦¿²¤¿¤­¤ê¤È¤Ê¤ê¤Þ¤¹¤¬¡¢Æäˣ·ºÐ°Ê²¼¤Çȯ¾É¤·¤¿¾ì¹ç¤Î¿Ê¹Ô¤ÏÁᤤ¤è¤¦¤Ç¤¹¡£AMN¤Ï°ìÈ̤ˤæ¤Ã¤¯¤ê¤·¤¿·Ð²á¤ÇÃÎŪ¥ì¥Ù¥ë¤¬Êݤ¿¤ì¤ë¤È¤µ¤ì¤Æ¤¤¤Þ¤¹¤¬¡¢ÌóȾ¿ô¤Ïȯɸå10ǯ°Ê¾å·Ð²á¤¹¤ë¤ÈÂçǾ¾É¾õ¤ò¹çÊ»¤·¤Æ¤¯¤ë¤è¤¦¤Ç¤¹¡£¾®Ç¾¡¦Ç¾´´·¿¤âÌóȾ¿ôÎ㤬ÂçǾ¾É¾õ¤ò¹çÊ»¤·¤Þ¤¹¡£

²È²Îò¡§ALD¤Ç¤ÏƱ°ì²È·ÏÆâ¤Ç¤â°Û¤Ê¤ëÎ×¾²É·¿¤Î´µ¼Ô¤¬È¯À¸¤·¤Þ¤¹¡£·»Äï´Ö¤Ç°Û¤Ê¤ëÉ·¿¤ò¼¨¤·¤¿¤Î¤Ï25¡ó¡¢¤ª¤¸±ù´Ö¤Ç¤Ï67¡ó¤Ç¤·¤¿¡£
¡ÊÎëÌÚ¹¯Ç·¡¢´ôÉìÂç³Ø°å³ØÉô°å³Ø¶µ°é³«È¯¸¦µæ¥»¥ó¥¿¡¼¡Ë

ʸ¸¥

  1. Takemoto Y, Suzuki Y, Shimozawa N, Tamakoshi A, Onodera O, Tsuji S, Kondo N. Epidemiology of X-linked adrenoleukodystrophy in Japan. J Hum Genet 47, 590-593 (2002)
  2. Moser HW, Smith KD, Watkins PA, Powers J, Moser AB (2001) X-linked Adrenoleukodystrophy. In: Scriver CR, Beaudet AL, Sly WS, Valle D eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. Vol. 2 New York: McGraw-Hill, 3257-3301
  3. van Geel BM, Assies J, Weverling GJ, Barth PG (1994) Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in the Netherlands: a survey of 30 kind reds. Neurology 44:2343-2346
  4. Ruiz M, Coll MJ, Pampols T, Giros M (1998) X-linked adrenoleukodystrophy: phenotype distribution and expression of ALDP in Spanish kind reds. Am J Med Genet 76:424-427
ÆüËܤˤª¤±¤ëALD¤Î±Ö³Ø¡Ê1990¡Á1999¡Ë
É·¿ ¡ó ȯ¾ÉǯÎð¡ÊÈÏ°Ï¡Ë È¯¾É¡Á¿ÇÃÇ
¾®»ù 29.9% 7.1(2-10ºÐ) 0.9ǯ
»×½Õ´ü 9.1 14.7 (11-19) 1.6
AMN 25.3 30.2 (13-51) 5.8
À®¿ÍÂçǾ 21.4 36.8 (21-58) 3.2
¾®Ç¾Ç¾´´ 8.4 38.0 (17-52) 5.4
ALDÁ´ÂΤÎȯ¾ÉÉÑÅÙ